Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Lana Castellucci et al, adding:
“Important paper for clinical practice.
A large study, independent of the pharma industry, found that in the setting of acute venous thrombosis, the risk of clinically relevant bleeding was:
- 3.3 percent with Apixaban
- 7.3 percent with Rivaroxaban
This difference was significant.
Congratulations to Lana Castellucci for coordinating this multicentre study.
We await the results of their AF study with interest.
Considering how many patients worldwide are on these drugs, this will be an impactful study.
The attached figure gives the summary.
The original article in this week’s New England Journal of Medicine is behind a paywall.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment
-
Oct 19, 2026, 16:04Hussnain Javaid: New EHA Guidelines for HbSC Disease Management
-
Oct 19, 2026, 15:50Deep Madkaiker: A New Academic Opportunity in Transfusion Medicine at ACTREC
-
Oct 19, 2026, 15:19Why Hematologists Should Care About Diminished Ovarian Reserve in SCD – ASH Education
-
Oct 19, 2026, 14:16Hyperfibrinolysis as an Underrecognized Cause of Bleeding
-
Oct 19, 2026, 13:36Shobhna Ladva: Aspen Pharma EME Raises Awareness of Blood Clot Risks During Hormonal Transitions
-
Oct 19, 2026, 13:11Giulia Furnari: Connecting With Global Hematology Experts at IACH 2026
-
Oct 19, 2026, 12:46Andrew Choong: Recognizing Thrombosis Before It Becomes Life-Threatening